Loading…
Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
Current knowledge of the reasons for patients' preference for rheumatoid arthritis (RA) treatment modes is limited. This study was designed to identify preferences for four treatment modes, and to obtain in-depth information on the reasons for these preferences. In this multi-national, cross-se...
Saved in:
Published in: | Patient preference and adherence 2020-01, Vol.14, p.119-131 |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c615t-b295975e9267b39cd88638793941cd0e51a5e44f9b68a46dcad704543b2117963 |
---|---|
cites | |
container_end_page | 131 |
container_issue | |
container_start_page | 119 |
container_title | Patient preference and adherence |
container_volume | 14 |
creator | Taylor, Peter C Betteridge, Neil Brown, T Michelle Woolcott, John Kivitz, Alan J Zerbini, Cristiano Whalley, Diane Olayinka-Amao, Oyebimpe Chen, Connie Dahl, Palle Ponce de Leon, Dario Gruben, David Fallon, Lara |
description | Current knowledge of the reasons for patients' preference for rheumatoid arthritis (RA) treatment modes is limited. This study was designed to identify preferences for four treatment modes, and to obtain in-depth information on the reasons for these preferences.
In this multi-national, cross-sectional, qualitative study, in-depth interviews were conducted with adult patients with RA in the United States, France, Germany, Italy, Spain, Switzerland, the United Kingdom, and Brazil. Patients' strength of preference was evaluated using a 100-point allocation task (0-100; 100=strongest) across four treatment modes: oral, self-injection, clinic-injection, and infusion. Qualitative descriptive analysis methods were used to identify, characterize, and summarize patterns found in the interview data relating to reasons for these preferences.
100 patients were interviewed (female, 75.0%; mean age, 53.9 years; mean 11.6 years since diagnosis). Among the four treatment modes, oral administration was allocated the highest mean (standard deviation) preference points (47.3 [33.1]) and was ranked first choice by the greatest percentage of patients (57.0%), followed by self-injection (29.7 [27.7]; 29.0%), infusion (15.4 [24.6]; 16.0%), and clinic-injection (7.5 [14.1]; 2.0%). Overall, 56.0% of patients had a "strong" first-choice preference (ie, point allocation ≥70); most of these patients chose oral (62.5%) vs self-injection (23.2%), infusion (10.7%), or clinic-injection (3.6%). Speed and/or ease of administration were the most commonly reported reasons for patients choosing oral (52.6%) or self-injection (55.2%). The most common reasons for patients not choosing oral or self-injection were not wanting to take another pill (37.2%) and avoiding pain due to needles (46.5%), respectively.
These data report factors important to patients regarding preferences for RA treatment modes. Patients may benefit from discussions with their healthcare professionals and/or patient support groups, regarding RA treatment modes, to facilitate shared decision-making. |
doi_str_mv | 10.2147/PPA.S220714 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_43b0f3bcd13845bb99654c889ec7e055</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A622161184</galeid><doaj_id>oai_doaj_org_article_43b0f3bcd13845bb99654c889ec7e055</doaj_id><sourcerecordid>A622161184</sourcerecordid><originalsourceid>FETCH-LOGICAL-c615t-b295975e9267b39cd88638793941cd0e51a5e44f9b68a46dcad704543b2117963</originalsourceid><addsrcrecordid>eNptkt1rFDEUxQdRbK0--S4Dggiya74z8UFY6lehxcWu0LeQSe7spM5MajJT8b836651VyQPCTe_e8I9OUXxFKM5wUy-Xi4X80tCkMTsXnGMsZSzqlJX9_fOR8WjlK4RElQQ_LA4ogQRjAk9Lq5WEczYwzCWF8FBuYzQQITBQir9UH5pYerNGLwrF3Fsox99epPJWz-sy1X4YaIrL1sTwZXvwPrkwzC7MN_y7ePiQWO6BE92-0nx9cP71emn2fnnj2eni_OZFZiPs5ooriQHRYSsqbKuqgStpKKKYesQcGw4MNaoWlSGCWeNk4hxRus8gFSCnhRnW10XzLW-ib438acOxuvfhRDX2sTR2w50bkINra3DtGK8rpUSnNnsD1gJiPOs9XardTPVPTibXYmmOxA9vBl8q9fhVgtVoYrhLPByJxDD9wnSqHufLHSdGSBMSRPKMauk4Cijz_9Br8MUh2zVhhKUYknpX2pt8gB-aEJ-125E9UIQggXGFcvU_D9UXg56b8MAjc_1g4YXew0tmG5sU-imMf9fOgRfbUEbQ0o5G3dmYKQ36dM5fXqXvkw_2_fvjv0TN_oLA_nRMA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2356331733</pqid></control><display><type>article</type><title>Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making</title><source>PubMed (Medline)</source><source>Access via Taylor & Francis (Open Access Collection)</source><source>Publicly Available Content (ProQuest)</source><creator>Taylor, Peter C ; Betteridge, Neil ; Brown, T Michelle ; Woolcott, John ; Kivitz, Alan J ; Zerbini, Cristiano ; Whalley, Diane ; Olayinka-Amao, Oyebimpe ; Chen, Connie ; Dahl, Palle ; Ponce de Leon, Dario ; Gruben, David ; Fallon, Lara</creator><creatorcontrib>Taylor, Peter C ; Betteridge, Neil ; Brown, T Michelle ; Woolcott, John ; Kivitz, Alan J ; Zerbini, Cristiano ; Whalley, Diane ; Olayinka-Amao, Oyebimpe ; Chen, Connie ; Dahl, Palle ; Ponce de Leon, Dario ; Gruben, David ; Fallon, Lara</creatorcontrib><description>Current knowledge of the reasons for patients' preference for rheumatoid arthritis (RA) treatment modes is limited. This study was designed to identify preferences for four treatment modes, and to obtain in-depth information on the reasons for these preferences.
In this multi-national, cross-sectional, qualitative study, in-depth interviews were conducted with adult patients with RA in the United States, France, Germany, Italy, Spain, Switzerland, the United Kingdom, and Brazil. Patients' strength of preference was evaluated using a 100-point allocation task (0-100; 100=strongest) across four treatment modes: oral, self-injection, clinic-injection, and infusion. Qualitative descriptive analysis methods were used to identify, characterize, and summarize patterns found in the interview data relating to reasons for these preferences.
100 patients were interviewed (female, 75.0%; mean age, 53.9 years; mean 11.6 years since diagnosis). Among the four treatment modes, oral administration was allocated the highest mean (standard deviation) preference points (47.3 [33.1]) and was ranked first choice by the greatest percentage of patients (57.0%), followed by self-injection (29.7 [27.7]; 29.0%), infusion (15.4 [24.6]; 16.0%), and clinic-injection (7.5 [14.1]; 2.0%). Overall, 56.0% of patients had a "strong" first-choice preference (ie, point allocation ≥70); most of these patients chose oral (62.5%) vs self-injection (23.2%), infusion (10.7%), or clinic-injection (3.6%). Speed and/or ease of administration were the most commonly reported reasons for patients choosing oral (52.6%) or self-injection (55.2%). The most common reasons for patients not choosing oral or self-injection were not wanting to take another pill (37.2%) and avoiding pain due to needles (46.5%), respectively.
These data report factors important to patients regarding preferences for RA treatment modes. Patients may benefit from discussions with their healthcare professionals and/or patient support groups, regarding RA treatment modes, to facilitate shared decision-making.</description><identifier>ISSN: 1177-889X</identifier><identifier>EISSN: 1177-889X</identifier><identifier>DOI: 10.2147/PPA.S220714</identifier><identifier>PMID: 32021123</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Antiarthritic agents ; Antirheumatic agents ; Arthritis ; Baricitinib ; Care and treatment ; Clinical decision making ; Decision making ; drug administration ; Hypothesis testing ; Interviews ; Medical personnel ; Medical research ; Original Research ; Pain ; patient perspective ; Patients ; Pharmaceutical industry ; Physicians ; Preferences ; Qualitative research ; Quality of life ; Rankings ; Rheumatoid arthritis ; Rheumatoid factor ; surveys ; Tofacitinib</subject><ispartof>Patient preference and adherence, 2020-01, Vol.14, p.119-131</ispartof><rights>2020 Taylor et al.</rights><rights>COPYRIGHT 2020 Dove Medical Press Limited</rights><rights>2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Taylor et al. 2020 Taylor et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c615t-b295975e9267b39cd88638793941cd0e51a5e44f9b68a46dcad704543b2117963</citedby><orcidid>0000-0003-3516-5289 ; 0000-0001-7766-6167</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2356331733/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2356331733?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32021123$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taylor, Peter C</creatorcontrib><creatorcontrib>Betteridge, Neil</creatorcontrib><creatorcontrib>Brown, T Michelle</creatorcontrib><creatorcontrib>Woolcott, John</creatorcontrib><creatorcontrib>Kivitz, Alan J</creatorcontrib><creatorcontrib>Zerbini, Cristiano</creatorcontrib><creatorcontrib>Whalley, Diane</creatorcontrib><creatorcontrib>Olayinka-Amao, Oyebimpe</creatorcontrib><creatorcontrib>Chen, Connie</creatorcontrib><creatorcontrib>Dahl, Palle</creatorcontrib><creatorcontrib>Ponce de Leon, Dario</creatorcontrib><creatorcontrib>Gruben, David</creatorcontrib><creatorcontrib>Fallon, Lara</creatorcontrib><title>Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making</title><title>Patient preference and adherence</title><addtitle>Patient Prefer Adherence</addtitle><description>Current knowledge of the reasons for patients' preference for rheumatoid arthritis (RA) treatment modes is limited. This study was designed to identify preferences for four treatment modes, and to obtain in-depth information on the reasons for these preferences.
In this multi-national, cross-sectional, qualitative study, in-depth interviews were conducted with adult patients with RA in the United States, France, Germany, Italy, Spain, Switzerland, the United Kingdom, and Brazil. Patients' strength of preference was evaluated using a 100-point allocation task (0-100; 100=strongest) across four treatment modes: oral, self-injection, clinic-injection, and infusion. Qualitative descriptive analysis methods were used to identify, characterize, and summarize patterns found in the interview data relating to reasons for these preferences.
100 patients were interviewed (female, 75.0%; mean age, 53.9 years; mean 11.6 years since diagnosis). Among the four treatment modes, oral administration was allocated the highest mean (standard deviation) preference points (47.3 [33.1]) and was ranked first choice by the greatest percentage of patients (57.0%), followed by self-injection (29.7 [27.7]; 29.0%), infusion (15.4 [24.6]; 16.0%), and clinic-injection (7.5 [14.1]; 2.0%). Overall, 56.0% of patients had a "strong" first-choice preference (ie, point allocation ≥70); most of these patients chose oral (62.5%) vs self-injection (23.2%), infusion (10.7%), or clinic-injection (3.6%). Speed and/or ease of administration were the most commonly reported reasons for patients choosing oral (52.6%) or self-injection (55.2%). The most common reasons for patients not choosing oral or self-injection were not wanting to take another pill (37.2%) and avoiding pain due to needles (46.5%), respectively.
These data report factors important to patients regarding preferences for RA treatment modes. Patients may benefit from discussions with their healthcare professionals and/or patient support groups, regarding RA treatment modes, to facilitate shared decision-making.</description><subject>Antiarthritic agents</subject><subject>Antirheumatic agents</subject><subject>Arthritis</subject><subject>Baricitinib</subject><subject>Care and treatment</subject><subject>Clinical decision making</subject><subject>Decision making</subject><subject>drug administration</subject><subject>Hypothesis testing</subject><subject>Interviews</subject><subject>Medical personnel</subject><subject>Medical research</subject><subject>Original Research</subject><subject>Pain</subject><subject>patient perspective</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Physicians</subject><subject>Preferences</subject><subject>Qualitative research</subject><subject>Quality of life</subject><subject>Rankings</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatoid factor</subject><subject>surveys</subject><subject>Tofacitinib</subject><issn>1177-889X</issn><issn>1177-889X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkt1rFDEUxQdRbK0--S4Dggiya74z8UFY6lehxcWu0LeQSe7spM5MajJT8b836651VyQPCTe_e8I9OUXxFKM5wUy-Xi4X80tCkMTsXnGMsZSzqlJX9_fOR8WjlK4RElQQ_LA4ogQRjAk9Lq5WEczYwzCWF8FBuYzQQITBQir9UH5pYerNGLwrF3Fsox99epPJWz-sy1X4YaIrL1sTwZXvwPrkwzC7MN_y7ePiQWO6BE92-0nx9cP71emn2fnnj2eni_OZFZiPs5ooriQHRYSsqbKuqgStpKKKYesQcGw4MNaoWlSGCWeNk4hxRus8gFSCnhRnW10XzLW-ib438acOxuvfhRDX2sTR2w50bkINra3DtGK8rpUSnNnsD1gJiPOs9XardTPVPTibXYmmOxA9vBl8q9fhVgtVoYrhLPByJxDD9wnSqHufLHSdGSBMSRPKMauk4Cijz_9Br8MUh2zVhhKUYknpX2pt8gB-aEJ-125E9UIQggXGFcvU_D9UXg56b8MAjc_1g4YXew0tmG5sU-imMf9fOgRfbUEbQ0o5G3dmYKQ36dM5fXqXvkw_2_fvjv0TN_oLA_nRMA</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Taylor, Peter C</creator><creator>Betteridge, Neil</creator><creator>Brown, T Michelle</creator><creator>Woolcott, John</creator><creator>Kivitz, Alan J</creator><creator>Zerbini, Cristiano</creator><creator>Whalley, Diane</creator><creator>Olayinka-Amao, Oyebimpe</creator><creator>Chen, Connie</creator><creator>Dahl, Palle</creator><creator>Ponce de Leon, Dario</creator><creator>Gruben, David</creator><creator>Fallon, Lara</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7XB</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>KB0</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3516-5289</orcidid><orcidid>https://orcid.org/0000-0001-7766-6167</orcidid></search><sort><creationdate>20200101</creationdate><title>Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making</title><author>Taylor, Peter C ; Betteridge, Neil ; Brown, T Michelle ; Woolcott, John ; Kivitz, Alan J ; Zerbini, Cristiano ; Whalley, Diane ; Olayinka-Amao, Oyebimpe ; Chen, Connie ; Dahl, Palle ; Ponce de Leon, Dario ; Gruben, David ; Fallon, Lara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c615t-b295975e9267b39cd88638793941cd0e51a5e44f9b68a46dcad704543b2117963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antiarthritic agents</topic><topic>Antirheumatic agents</topic><topic>Arthritis</topic><topic>Baricitinib</topic><topic>Care and treatment</topic><topic>Clinical decision making</topic><topic>Decision making</topic><topic>drug administration</topic><topic>Hypothesis testing</topic><topic>Interviews</topic><topic>Medical personnel</topic><topic>Medical research</topic><topic>Original Research</topic><topic>Pain</topic><topic>patient perspective</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Physicians</topic><topic>Preferences</topic><topic>Qualitative research</topic><topic>Quality of life</topic><topic>Rankings</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatoid factor</topic><topic>surveys</topic><topic>Tofacitinib</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taylor, Peter C</creatorcontrib><creatorcontrib>Betteridge, Neil</creatorcontrib><creatorcontrib>Brown, T Michelle</creatorcontrib><creatorcontrib>Woolcott, John</creatorcontrib><creatorcontrib>Kivitz, Alan J</creatorcontrib><creatorcontrib>Zerbini, Cristiano</creatorcontrib><creatorcontrib>Whalley, Diane</creatorcontrib><creatorcontrib>Olayinka-Amao, Oyebimpe</creatorcontrib><creatorcontrib>Chen, Connie</creatorcontrib><creatorcontrib>Dahl, Palle</creatorcontrib><creatorcontrib>Ponce de Leon, Dario</creatorcontrib><creatorcontrib>Gruben, David</creatorcontrib><creatorcontrib>Fallon, Lara</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Patient preference and adherence</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taylor, Peter C</au><au>Betteridge, Neil</au><au>Brown, T Michelle</au><au>Woolcott, John</au><au>Kivitz, Alan J</au><au>Zerbini, Cristiano</au><au>Whalley, Diane</au><au>Olayinka-Amao, Oyebimpe</au><au>Chen, Connie</au><au>Dahl, Palle</au><au>Ponce de Leon, Dario</au><au>Gruben, David</au><au>Fallon, Lara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making</atitle><jtitle>Patient preference and adherence</jtitle><addtitle>Patient Prefer Adherence</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>14</volume><spage>119</spage><epage>131</epage><pages>119-131</pages><issn>1177-889X</issn><eissn>1177-889X</eissn><abstract>Current knowledge of the reasons for patients' preference for rheumatoid arthritis (RA) treatment modes is limited. This study was designed to identify preferences for four treatment modes, and to obtain in-depth information on the reasons for these preferences.
In this multi-national, cross-sectional, qualitative study, in-depth interviews were conducted with adult patients with RA in the United States, France, Germany, Italy, Spain, Switzerland, the United Kingdom, and Brazil. Patients' strength of preference was evaluated using a 100-point allocation task (0-100; 100=strongest) across four treatment modes: oral, self-injection, clinic-injection, and infusion. Qualitative descriptive analysis methods were used to identify, characterize, and summarize patterns found in the interview data relating to reasons for these preferences.
100 patients were interviewed (female, 75.0%; mean age, 53.9 years; mean 11.6 years since diagnosis). Among the four treatment modes, oral administration was allocated the highest mean (standard deviation) preference points (47.3 [33.1]) and was ranked first choice by the greatest percentage of patients (57.0%), followed by self-injection (29.7 [27.7]; 29.0%), infusion (15.4 [24.6]; 16.0%), and clinic-injection (7.5 [14.1]; 2.0%). Overall, 56.0% of patients had a "strong" first-choice preference (ie, point allocation ≥70); most of these patients chose oral (62.5%) vs self-injection (23.2%), infusion (10.7%), or clinic-injection (3.6%). Speed and/or ease of administration were the most commonly reported reasons for patients choosing oral (52.6%) or self-injection (55.2%). The most common reasons for patients not choosing oral or self-injection were not wanting to take another pill (37.2%) and avoiding pain due to needles (46.5%), respectively.
These data report factors important to patients regarding preferences for RA treatment modes. Patients may benefit from discussions with their healthcare professionals and/or patient support groups, regarding RA treatment modes, to facilitate shared decision-making.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>32021123</pmid><doi>10.2147/PPA.S220714</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-3516-5289</orcidid><orcidid>https://orcid.org/0000-0001-7766-6167</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1177-889X |
ispartof | Patient preference and adherence, 2020-01, Vol.14, p.119-131 |
issn | 1177-889X 1177-889X |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_43b0f3bcd13845bb99654c889ec7e055 |
source | PubMed (Medline); Access via Taylor & Francis (Open Access Collection); Publicly Available Content (ProQuest) |
subjects | Antiarthritic agents Antirheumatic agents Arthritis Baricitinib Care and treatment Clinical decision making Decision making drug administration Hypothesis testing Interviews Medical personnel Medical research Original Research Pain patient perspective Patients Pharmaceutical industry Physicians Preferences Qualitative research Quality of life Rankings Rheumatoid arthritis Rheumatoid factor surveys Tofacitinib |
title | Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A43%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20Mode%20Preferences%20in%20Rheumatoid%20Arthritis:%20Moving%20Toward%20Shared%20Decision-Making&rft.jtitle=Patient%20preference%20and%20adherence&rft.au=Taylor,%20Peter%20C&rft.date=2020-01-01&rft.volume=14&rft.spage=119&rft.epage=131&rft.pages=119-131&rft.issn=1177-889X&rft.eissn=1177-889X&rft_id=info:doi/10.2147/PPA.S220714&rft_dat=%3Cgale_doaj_%3EA622161184%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c615t-b295975e9267b39cd88638793941cd0e51a5e44f9b68a46dcad704543b2117963%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2356331733&rft_id=info:pmid/32021123&rft_galeid=A622161184&rfr_iscdi=true |